Options for Effective Treatment of Visceral Leishmaniasis

  title={Options for Effective Treatment of Visceral Leishmaniasis},
  author={S. Bhattacharya and J. Khan and P. Sinha and Sabahat Azim},
  journal={Current Treatment Options in Infectious Diseases},
  • S. Bhattacharya, J. Khan, +1 author Sabahat Azim
  • Published 2017
  • Medicine
  • Current Treatment Options in Infectious Diseases
  • Opinion statementVisceral Leishmaniasis (VL), also known as kala-azar, is caused by several species of Leishmania, a protozoan parasite (Leishmania donovani) transmitted to humans by the bite of infected phelobotomine argentipes sandflies. VL is a disease of poverty, affecting the poorest of the poor. It is a major cause of morbidity and mortality in some areas (localized). If the infection is left untreated, the patient dies in about 2 years. Several drugs are now available for the treatment… CONTINUE READING


    Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study.
    • 114
    • PDF
    Injectable paromomycin for Visceral leishmaniasis in India.
    • 366
    • PDF
    A phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya.
    • 123
    • PDF
    Antiparasitic agents.
    • 46
    Asymptomatic Leishmania infection: a new challenge for Leishmania control.
    • 102
    • PDF
    Visceral leishmaniasis and tuberculosis in patients with HIV co-infection.
    • 5
    • PDF